Sonja Witteveen, MD, The Netherlands Cancer Institute, Amsterdam, Netherlands, discusses three-year outcomes from the Phase III NADINA (NCT04949113) trial comparing neoadjuvant ipilimumab plus nivolumab, followed by response-driven adjuvant therapy, versus surgery and adjuvant nivolumab in resectable stage III melanoma. The neoadjuvant approach continued to show significantly superior event-free and distant metastasis-free survival across all subgroups. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.